

Versartis, Inc.
Form 3
March 20, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

<p>1. Name and Address of Reporting Person *</p> <p>Â Malik Shahzad</p> <p>(Last) (First) (Middle)</p> <p>C/O ADVENT LIFE SCIENCES,Â 158 NORTH GOWER STREET</p> <p>(Street)</p> <p>LONDON,Â X0Â NW1 2ND</p> <p>(City) (State) (Zip)</p>	<p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>03/20/2014</p>	<p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Versartis, Inc. [VSAR]</p>	<p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p>	<p>5. If Amendment, Date Original Filed(Month/Day/Year)</p>	<p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person</p>
---	---	--	--	---	---

Table I - Non-Derivative Securities Beneficially Owned

<p>1. Title of Security (Instr. 4)</p>	<p>2. Amount of Securities Beneficially Owned (Instr. 4)</p>	<p>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</p>	<p>4. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
--	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<p>1. Title of Derivative Security (Instr. 4)</p>	<p>2. Date Exercisable and Expiration Date (Month/Day/Year)</p> <p>Date Exercisable Expiration Date</p>	<p>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</p> <p>Title Amount or Number of</p>	<p>4. Conversion or Exercise Price of Derivative Security</p>	<p>5. Ownership Form of Derivative Security: Direct (D)</p>	<p>6. Nature of Indirect Beneficial Ownership (Instr. 5)</p>
---	--	--	---	---	--

Edgar Filing: Versartis, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Series B Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	49,132	\$ (1)	I	See FN (3)
Series B Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	1,164,923	\$ (1)	I	See FN (4)
Series C Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	19,815	\$ (1)	I	See FN (3)
Series C Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	469,438	\$ (1)	I	See FN (4)
Series D-1 Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	7,158	\$ (1)	I	See FN (3)
Series D-1 Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	169,655	\$ (1)	I	See FN (4)
Series D-2 Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	3,167	\$ (1)	I	See FN (3)
Series D-2 Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	75,061	\$ (1)	I	See FN (4)
Series E Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	6,240	\$ (1)	I	See FN (3)
Series E Convertible Preferred Stock	Â (1)	Â (2)	Common Stock	147,938	\$ (1)	I	See FN (4)
Warrant to Purchase Series B Convertible Preferred Stock	Â (5)	Â (6)	Series B Convertible Preferred Stock	20,457	\$ 0.45	I	See FN (3)
Warrant to Purchase Series B Convertible Preferred Stock	Â (5)	Â (6)	Series B Convertible Preferred Stock	485,919	\$ 0.45	I	See FN (4)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Malik Shahzad C/O ADVENT LIFE SCIENCES 158 NORTH GOWER STREET LONDON, X0 NW1 2ND	Â X	Â X	Â	Â

Signatures

/s/ Shahzad
Malik

03/20/2014

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- In connection with the completion of the Issuer's initial public offering of Common Stock, each share of Series B Convertible Preferred Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock shall automatically convert into Common Stock on a 1-for-11.5 basis.
- (1) Stock, Series C Convertible Preferred Stock, Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock shall automatically convert into Common Stock on a 1-for-11.5 basis.
 - (2) Not applicable.
 - (3) Represents securities held by Advent Life Sciences LLP. The reporting person is a partner of Advent Life Sciences LLP.
 - (4) Represents securities held by Advent Life Sciences Fund I LP. Advent Life Sciences LLP is the general partner of Advent Life Sciences Fund I LP and the reporting person is a partner of Advent Life Sciences LLP.
 - (5) In connection with the completion of the Issuer's initial public offering of Common Stock the warrant to purchase Series B Convertible Preferred Stock shall automatically convert into a warrant to purchase Common Stock on a 1-for-11.5 basis.
 - (6) The warrant shall expire on the earlier of October 12, 2017 or the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.